High prices for orphan drugs strain families, insurers
Consumer Corner January 22, 2017 Kaiser Health News 0
The orphan drug program overseen by the FDA is loaded with government incentives and has helped hundreds of thousands of patients feel better or even stay alive, but the program has opened the door to almost unlimited price tags and created incentives for drug makers to cash in, and to cash in repeatedly.
Health care at Legislature
Apr 17, 2021 0
Vaccinating Latino employees
Apr 13, 2021 0
Sluggish vaccine rollout
Mar 14, 2021 0
No comments so far.
Be first to leave comment below.